AbCellera Biologics (ABCL) Tax Provisions (2021 - 2026)
AbCellera Biologics' (ABCL) quarterly Tax Provisions came in at -$6.4 million in Q1 2026, up 13.46% YoY from -$5.6 million in Q1 2025, and up 39.62% on a QoQ basis from -$10.6 million in Q4 2025.
AbCellera Biologics (ABCL) Tax Provisions (2021 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 6 years of Tax Provisions data on file, last reported at -$6.4 million in Q1 2026.
- Quarterly Tax Provisions rose 13.46% year-over-year to -$6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$30.2 million (up 29.4% YoY) and the FY2025 annual result came in at -$31.2 million, up 16.93% from the prior year.
- Tax Provisions improved to -$6.4 million in Q1 2026, from -$10.6 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $62.2 million in Q1 2022 to a low of -$12.6 million in Q4 2024.
- A 5-year average of -$1.3 million and a median of -$7.4 million in 2025 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2022 — Tax Provisions jumped 655.76% — and 2023, when it tumbled 7301.98%.
- Tracing ABCL's Tax Provisions over 5 years: stood at -$1.5 million in 2022, then climbed by 4.41% to -$1.5 million in 2023, then sank by 769.08% to -$12.6 million in 2024, then rose by 16.36% to -$10.6 million in 2025, then soared by 39.62% to -$6.4 million in 2026.
- The last three Tax Provisions figures came in at -$6.4 million (Q1 2026), -$10.6 million (Q4 2025), and -$11.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | -3.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.54 Mn |
| Mar 31, 2026 | -6.37 Mn |
| Dec 31, 2025 | -10.55 Mn |
| Sep 30, 2025 | -11.65 Mn |
| Jun 30, 2025 | -1.62 Mn |
| Mar 31, 2025 | -7.36 Mn |
| Dec 31, 2024 | -12.62 Mn |
| Sep 30, 2024 | -11.53 Mn |
| Jun 30, 2024 | -11.26 Mn |
| Mar 31, 2024 | -2.14 Mn |
| Dec 31, 2023 | -1.45 Mn |
| Sep 30, 2023 | -10.67 Mn |
| Jun 30, 2023 | -7.48 Mn |
| Mar 31, 2023 | -8.04 Mn |
| Dec 31, 2022 | -1.52 Mn |
| Sep 30, 2022 | 19.96 Mn |
| Jun 30, 2022 | -101,000.00 |
| Mar 31, 2022 | 62.24 Mn |
| Dec 31, 2021 | 24.76 Mn |
| Sep 30, 2021 | -3.59 Mn |